Khiron Life Sciences (Khiron Life Sciences) Debt-to-Equity : 0.10 (As of Sep. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Khiron Life Sciences Debt-to-Equity?

Khiron Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.92 Mil. Khiron Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $1.00 Mil. Khiron Life Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $20.32 Mil. Khiron Life Sciences's debt to equity for the quarter that ended in Sep. 2022 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Khiron Life Sciences's Debt-to-Equity or its related term are showing as below:

KHRNF's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

Khiron Life Sciences Debt-to-Equity Historical Data

The historical data trend for Khiron Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Debt-to-Equity Chart

Khiron Life Sciences Annual Data

Trend

May12

May13

May14

May15

May16

May17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.05

0.04

0.07

Khiron Life Sciences Quarterly Data
	Nov17	Feb18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.07	0.09	0.08	0.10

Competitive Comparison of Khiron Life Sciences's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Khiron Life Sciences's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's Debt-to-Equity falls into.

Khiron Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Khiron Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.189	+	0.551)	/	26.038
	=	0.07

Khiron Life Sciences's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.919	+	1.003)	/	20.319
	=	0.09

Khiron Life Sciences (OTCPK:KHRNF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Khiron Life Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Khiron Life Sciences (Khiron Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRNF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5

Website

https://www.khiron.ca

Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.